All In Biotech

NDA 022070 · Dow Pharm

Atralin

Tretinoin · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: Jan 5, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jul 26, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

375

82 Phase 3, 25 recruiting

FAERS reports

6,575

4,123 serious, 851 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 1, 2024.

Atralin Gel is indicated for topical treatment of acne vulgaris. Atralin Gel is a retinoid indicated for topical treatment of acne vulgaris. ( 1 )

Mechanism: Tretinoin is a metabolite of Vitamin A that binds with high affinity to specific retinoic acid receptors located in both the cytosol and nucleus, but cutaneous levels of tretinoin in excess of physiologic concentrations occur following application of a tretinoin-containing topical drug product. Although tretinoin activates three members of the retinoid acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation, it has not been established whether the clinical effects of tretinoin are...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ATRALIN · TRETINOIN 0.05% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.

All 375 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use879
  • drug ineffective733
  • pain490
  • product use in unapproved indication484
  • vomiting452
  • paraesthesia373
  • abdominal pain upper369
  • rash364
  • nausea355
  • diarrhoea348
  • headache338
  • maternal exposure during pregnancy338

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200531
200624
200739
2008115
200972
201078
201191
2012153
2013101
2014155
2015233
2016354
2017350
2018460
2019353
2020376
2021428
2022512
2023568
2024674
2025809
2026562

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atralin (Tretinoin)

2024 spending

$9K

Beneficiaries

n/a

16 claims

Per beneficiary

n/a

$12.38 per unit

View as table
YearSpending
2020$29,393
2021$13,637
2022$10,229
2023$6,555
2024$8,916

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: Dow Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.